Stellar Announces New Board Members
Complete the form below to unlock access to ALL audio articles.
Stellar Biotechnologies, Inc. has announced that Gregory T. Baxter, Ph.D. and Mike Sampat have been appointed to the Board of Directors.
Stellar’s President & CEO, Frank Oakes said, “These two key appointments are important to the Company as they strengthen our independent corporate governance while adding a director who is a financial and deal-savvy CPA in Mike Sampat to fill the vacancy left by the passing of our board member Harvey Wright, and Greg Baxter, a scientist with experience as an executive and director in a number of biotech companies and institutions, including the National Science Foundation (NSF), where he had the opportunity to work closely with the Stellar team during the past three years. The independent perspective that Mike and Greg will bring, and the combination of experience in financial management, fund raising, and strong ties to the biotechnology industry bring strength to the board in key areas and should provide great support and guidance to the Company’s executive team.”
New director, Mike Sampat said, “I’m excited to join the Stellar board as the Company continues to grow to be a prime supplier of high-quality KLH to the pharmaceutical industry and look forward to expanding the capital base to fund the future growth.”
New board member, Greg Baxter said, “Stellar Biotechnologies is an exciting and innovative company and a leader in the sustainable manufacture of an important immune stimulating protein critical for the production of therapeutic vaccines and immunodiagnostics products. I am excited to be a part of the Stellar team and to have the opportunity to participate in the growth of the Company.”
